These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23050317)

  • 21. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
    Zarogoulidis P; Petridis D; Ritzoulis C; Darwiche K; Spyratos D; Huang H; Goldberg EP; Yarmus L; Li Q; Freitag L; Zarogoulidis K
    Int J Pharm; 2013 Sep; 453(2):480-7. PubMed ID: 23769993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of degradation products from aqueous carboplatin injection samples by electrospray mass spectrometry.
    Vivekanandan K; Swamy MG; Prasad S; Maikap GC; Mukherjee R; Burman AC
    Int J Pharm; 2006 Apr; 313(1-2):214-21. PubMed ID: 16529885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration.
    Trissel LA; Zhang Y; Xu QA
    Int J Pharm Compd; 2006; 10(3):234-6. PubMed ID: 23974237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical and chemical stability of palonosetron hydrochloride with Lorazepam and midazolam hydrochloride during simulated y-site administration.
    Trissel LA; Xu QA
    Int J Pharm Compd; 2005; 9(3):235-7. PubMed ID: 23924982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated y-site administration.
    Trissel LA; Xu QA
    Int J Pharm Compd; 2005; 9(3):238-41. PubMed ID: 23924983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seventy-two-hour stability of Taxol in 5% dextrose or 0.9% sodium chloride in Viaflo, Freeflex, Ecoflac and Macoflex N non-PVC bags.
    Pourroy B; Botta C; Solas C; Lacarelle B; Braguer D
    J Clin Pharm Ther; 2005 Oct; 30(5):455-8. PubMed ID: 16164492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
    Karnatz NN; Wong J; Kesler H; Baaske DM; Speicher ER
    Am J Hosp Pharm; 1988 Feb; 45(2):368-71. PubMed ID: 2896460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of cyclosporine with magnesium sulfate in 5% dextrose injection.
    Nieforth KA; Shea BF; Souney PF; Scavone JM
    Am J Hosp Pharm; 1993 Mar; 50(3):470-2. PubMed ID: 8442464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compatibility and stability of palonosetron hydrochloride with four neruomuscular blocking agents during simulated y-site administration.
    Trusley C; Ben M; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2008; 12(2):156-60. PubMed ID: 23969608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
    Stewart CF; Fleming RA
    Am J Hosp Pharm; 1990 Jun; 47(6):1373-7. PubMed ID: 2368735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.
    Mugabe C; Liggins RT; Guan D; Manisali I; Chafeeva I; Brooks DE; Heller M; Jackson JK; Burt HM
    Int J Pharm; 2011 Feb; 404(1-2):238-49. PubMed ID: 21093563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets.
    Trissel LA; Xu Q; Kwan J; Martinez JF
    Am J Hosp Pharm; 1994 Nov; 51(22):2804-10. PubMed ID: 7856604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.
    Xu QA; Trissel LA; Williams KY
    J Am Pharm Assoc (Wash); 2000; 40(4):509-14. PubMed ID: 10932460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.
    Hendrikx JJ; Hillebrand MJ; Thijssen B; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Oct; 879(28):2984-90. PubMed ID: 21920826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in paclitaxel and docetaxel interactions with tubulin detected by mutagenesis of yeast tubulin.
    Winefield RD; Entwistle RA; Foland TB; Lushington GH; Himes RH
    ChemMedChem; 2008 Dec; 3(12):1844-7. PubMed ID: 18988212
    [No Abstract]   [Full Text] [Related]  

  • 40. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Jul; 51(14):1792-9. PubMed ID: 7942908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.